(Natural News)—What could be more dangerous in the field of medicine than government officials knowingly licensing dangerous medical experiments on the population, and then suddenly taking up new positions with the pharmaceutical companies that they were supposed to regulate? This revolving door of corruption is currently taking place between the Food and Drug Administration (FDA) and Moderna, one of the manufacturers of COVID-19 “vaccines.” This collusion is the real public health threat, because it means there is no true regulatory oversight, no accountability for gross medical error and unchecked medical fraud.
When a little-known pharmaceutical company named Moderna was awarded $4.94 billion under Operation Warp Speed, the company suddenly wielded great influence over the regulatory bodies of the federal government. In fact, two high-level regulatory officials at the FDA took up new positions at Moderna just months after they granted Moderna a full licensure for their COVID-19 vaccines and booster shots. This corruption was brought to light thanks to an investigation by Peter Doshi, who published it in the British Medical Journal.
The revolving door of collusion between our government and Big Pharma
Moderna now employs former FDA employees who carelessly approved Moderna’s dangerous mRNA experiments.
Dr. Doran Fink
The first FDA vaccine regulator who went to work for Moderna is Dr. Doran Fink. Dr. Fink was a vaccine regulator at the FDA for more than 12 years; he was a “physician/scientist experienced in regulation and clinical development/licensure of vaccines and related biological products.” Back in 2010, Dr. Fink began his career with the FDA as a clinical reviewer. Soon, he worked his way up to becoming the Deputy Director of the Division of Vaccine and Related Product Applications within the FDA’s Office of Vaccine Research and Review.
When COVID-19 propaganda and lockdowns were in full force, Dr. Fink was up front pushing the experimental COVID-19 vaccines and all the lockdowns, isolation and coercion that went along with the program. He also helped designate which population groups should receive the shots first. He attended numerous FDA meetings arguing for the approval of the COVID-19 vaccines and an onslaught of new boosters. Dr. Fink headed up a senior leadership team for COVID-19 vaccine review and coordinated policies that subjugated, coerced, bribed and segregated individuals in order to increase vaccine uptake in the population. Most importantly, Dr. Fink engaged in a “senior level review” for the FDA’s emergency use authorization and licensure of the COVID-19 vaccines. He would go on to approve medical fraud, which included the Moderna COVID-19 vaccines.
After essentially granting Moderna a license to kill, Dr. Fink left his post at the FDA in December 2022. By February 2023, he started working for Moderna as the head of “Translational Medicine and Early Clinical Development, Infectious Diseases.” Now he helps the company come up with new, dangerous vaccine experiments that will one day be granted full FDA approval because Dr. Fink has tremendous influence over his colleagues at the FDA.
Dr. Java Goswami
The second FDA official to take advantage of her government position and influence is Dr. Jaya Goswami. In March of 2020, Dr. Goswami worked as a medical officer at the FDA’s Center for Biologics Evaluation and Research. Her role was to oversee the development of the COVID-19 vaccine in record time. Her responsibilities included having “broad oversight over vaccines and biologics clinical development.”
Dr. Goswami ultimately got to determine whether the clinical data for Moderna’s COVID-19 vaccine met the regulatory standards set by the FDA. By January 2022, Dr. Goswami helped grant a full FDA approval for Moderna’s Spikevax. By June 2022, Dr. Goswami left the FDA and began a job with Moderna as the director of clinical development in infectious diseases. Now Dr. Goswami helps develop new mRNA vaccines, which are on the fast track for FDA approval, because she has all the right connections at the FDA.
Kim Witczak, a global pharmaceutical drug safety advocate and member of the FDA’s Psychopharmacologic Drugs Advisory Committee, spoke with The Epoch Times about the corruption at the FDA and the need for a cooling off period to stall the corruption between industry and government. “The recurring issue of the revolving door culture between industry and regulators has long been a concern and raises questions about regulatory impartiality,” she said. “A troubling trend is the intentional career move of making a stop at a regulatory agency, with the real payoff occurring when they transition to drug company roles. While this might benefit the pharmaceutical industry, it poses risks to public health. The worry arises about potential bias in regulating practices, including being lenient in criticism or overlooking safety concerns.”
Sources include:
Bypass Big Tech Censors
Why Bullion Beats Numismatics and Collectible for Your Safe or IRA
Precious metals continue to attract Americans seeking reliable ways to protect their wealth amid inflation, geopolitical risks, and stock market swings. Whether stored in a home safe or held inside a self-directed IRA, physical gold and silver deliver tangible value that paper or digital assets often lack. Yet investors must choose carefully between bullion—pure bars and coins valued mainly for their metal content—and numismatics or collectibles, where rarity, history, and collector demand heavily influence pricing.
Advisor Bullion serves as a dependable source for straightforward, high-quality bullion. The company specializes in physical gold, silver, platinum, and palladium, emphasizing transparent pricing and products that deliver maximum metal content for every dollar spent. This approach makes it ideal for both personal holdings and retirement accounts.
Bullion consists of refined precious metals in standard forms like one-ounce coins (American Gold Eagles, Silver Eagles, Canadian Maple Leafs) or bars. Their value tracks closely to the current spot price of the metal. A typical gold bullion coin trades near the live gold spot price plus a small premium. This structure keeps costs clear and predictable.
Numismatic coins and collectibles add substantial value from factors such as age, rarity, minting errors, or historical significance. A pre-1933 U.S. gold coin or graded proof piece can carry premiums of 30%, 50%, or even 200% above melt value. While this appeals to hobbyists, it creates complexity. Pricing depends on subjective grading, collector trends, and auction results instead of daily spot prices.
For investors focused on wealth preservation and retirement security rather than building a collection, bullion often delivers better results.
Lower Costs and Better Liquidity for Home Storage
When keeping metals in a home safe or private vault, liquidity and efficiency count. Bullion offers clear benefits:
- You acquire more actual gold or silver per dollar invested. Numismatics divert a large share of your money into rarity premiums and massive sales commission, reducing your metal exposure.
- Selling bullion involves tight bid-ask spreads, so you recover nearly full spot value with minimal fees. Collectibles require finding the right buyer and may sell at a discount if demand for that specific item weakens.
- Bullion prices remain transparent and update with global spot markets. You can track gold near current levels or silver accordingly and know exactly where your holdings stand. Numismatic values are priced by the Gold IRA companies with hefty margins applied.
- Standardized coins and bars store efficiently and divide easily for partial sales. Rare coins often need protective slabs and controlled conditions, adding hassle and expense.
- Bullion enjoys worldwide acceptance. A 1-oz Gold Maple Leaf or Silver Eagle sells quickly to dealers anywhere. Niche numismatic pieces may appeal only to limited buyers, slowing liquidation when speed matters.
In times when quick access to value becomes important, bullion’s simplicity stands out.
Stronger Fit for Precious Metals IRAs
Precious metals IRAs continue gaining traction as investors diversify retirement portfolios beyond stocks and bonds. IRS rules permit certain bullion products in self-directed IRAs if they meet purity standards (.995 fine for gold, .999 for silver) and are held by an approved custodian. Eligible items include American Gold and Silver Eagles plus many generic bars and rounds from recognized mints.
Numismatic and most collectible coins generally face heavy scrutiny from custodians due to valuation disputes and elevated markups. These higher premiums mean less actual metal ends up working inside the account.
Bullion avoids these issues. Its value links directly to verifiable spot prices, which simplifies reporting and lowers the risk of regulatory challenges. More of your IRA contribution purchases real metal instead of dealer profits or speculative upside. Over time, owning additional ounces that appreciate with the metal itself can create meaningful outperformance compared with high-premium alternatives that deliver fewer ounces.
Regulatory guidance from the CFTC and state securities offices repeatedly cautions against aggressive sales of expensive numismatics or “semi-numismatic” coins for IRAs. For retirement planning, transparent bullion from established providers reduces risk and aligns better with long-term goals.
How to Get Started with Bullion
Begin by clarifying your goals. Are you protecting savings in a safe, or moving part of a retirement account into a precious metals IRA? Focus on the number of ounces you can acquire at current prices rather than chasing marked-up collectibles.
Diversify sensibly: use gold for core preservation and silver for its blend of industrial and monetary qualities. Mix coins for easier divisibility with bars for lower per-ounce costs on larger buys. Arrange secure storage—whether at home with proper insurance or through professional facilities.
As economic uncertainties linger and faith in conventional assets erodes, bullion continues proving its worth as a dependable store of value. Its direct approach avoids the hype that sometimes surrounds collectible markets and keeps the focus on the metal itself.
For investors prepared to strengthen their portfolios, Advisor Bullion supplies the expertise and selection needed to acquire high-quality bullion efficiently. Whether building personal holdings or integrating metals into an IRA, their emphasis on transparent, investment-grade products helps secure more ounces today that support greater financial security tomorrow. In a complicated financial landscape, bullion’s clarity and reliability make it the smarter foundation for protecting what matters most.